FOXO1 in Non-Alcoholic Fatty Liver Disease


HTRF® Application Note

Non-alcoholic fatty liver disease (NAFLD) includes a range of liver conditions unrelated to alcohol consumption that results in inflammation and fibrosis. NAFLD may progress to non-alcoholic steatohepatitis (NASH), cirrhosis, or liver failure; and is closely linked to metabolic syndromes through activation of glucose and lipogenesis-regulating transcription factors, such as FOXO1.

Download this complimentary application note to explore the use of an HTRF assay for the evaluation of FOXO1 in a fatty liver disease model and evaluate:

  • pro-inflammatory cytokine activation
  • the benefits of HTRF assays compared to western blot
  • a model system for fatty liver disease and insulin resistance